R&D Towards better quality of life, GNT Pharma

Clinical Research

ENIS IIIEfficacy and safety of Nelonemdaz (Neu2000) in acute Ischemic Stroke patients (PIII)

  • A Phase III clinical trial in China to verify safety and efficacy of nelonemdaz in 948 patients with moderate and severe acute stroke receiving thrombolytics within 8 hours after stroke onset.
  • Participating Hospitals (Department of Neurology): 39 university hospitals, including Tiantan Hospital, Capital Medical University in Beijing.
  • This trial commenced in September 2020 (first patient enrolled on December 25, 2020).
Total No. of
Enrolled Patients
Progress RateAs of June 7, 2022
314 Pts. 33.1%
Target No. of Patients 948 Pts.